
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx NV is advancing its clinical-stage product candidate, vilobelimab, a novel anti-C5a monoclonal antibody, demonstrating promising efficacy in treating autoimmune and inflammatory conditions. Clinical data indicate that vilobelimab significantly improves health scores, reduces disease severity, and enhances patient outcomes, with a marked reduction in all-cause mortality in treated populations. The therapy's ability to improve patient responses while being well tolerated indicates a strong potential for both clinical and commercial success as additional investigations are warranted.
Bears say
InflaRx NV faces a negative outlook primarily due to depressed forward multiples that are reflective of current market volatility, indicating potential challenges in attracting investor confidence. Additionally, the company's cash burn could significantly escalate as it navigates the various stages of development programs, with limited offset from partner or collaborative milestone revenues. Furthermore, there is a concerning commercial risk associated with partnered assets, which may experience diminishing demand and reduced market share due to evolving standards of care and competition from emerging therapies.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares